Practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care

Author:

Del Rivero Jaydira1ORCID,Mailman Josh2,Rabow Michael W3,Chan Jennifer A4,Creed Sarah5,Kennecke Hagen F6,Pasieka Janice7,Zuar Jennifer8,Singh Simron9,Fishbein Lauren10ORCID

Affiliation:

1. Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, USA

2. NorCal CarciNET Community, Oakland, California, USA

3. Department of Internal Medicine, Division of Palliative Medicine, University of California, San Francisco, San Francisco, California, USA

4. Harvard Medical School, Program in Carcinoid and Neuroendocrine Tumors, Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA

5. Good Shepherd Community Care, Harvard Kennedy School, Natick, Massachusetts, USA

6. Providence Cancer Institute Franz Clinic, Portland Providence Medical Center, Portland, Oregon, USA

7. Department of Surgery, Section of General Surgery, University of Calgary, Cumming School of Medicine, Calgary, Canada

8. Department of Internal Medicine, Division of Geriatrics and Palliative Medicine, Alpert Medical School, Providence, Rhode Island, USA

9. Odette Cancer Centre, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

10. Department of Medicine, Division of Endocrinology, Metabolism and Diabetes, Department of Biomedical Informatics, University of Colorado School of Medicine, Aurora, Colorado, USA

Abstract

This serves as a white paper by the North American Neuroendocrine Tumor Society (NANETS) on the practical considerations when providing palliative care to patients with neuroendocrine tumors in the context of routine disease management or hospice care. The authors involved in the development of this manuscript represent a multidisciplinary team of patient advocacy, palliative care, and hospice care practitioners, endocrinologist, and oncologists who performed a literature review and provided expert opinion on a series of questions often asked by our patients and patient caregivers affected by this disease. We hope this document serves as a starting point for oncologists, palliative care teams, hospice medical teams, insurers, drug manufacturers, caregivers, and patients to have a frank, well-informed discussion of what a patient needs to maximize the quality of life during a routine, disease-directed care as well as at the end-of-life.

Publisher

Bioscientifica

Subject

Cancer Research,Endocrinology,Oncology,Endocrinology, Diabetes and Metabolism

Reference70 articles.

1. Association of dose escalation of octreotide long-acting release on clinical symptoms and tumor markers and response among patients with neuroendocrine tumors,2015

2. WHO analgesic ladder;Anekar,2023

3. Role of diet in the management of carcinoid syndrome: clinical recommendations for nutrition in patients with neuroendocrine tumors;Artale,2020

4. Early versus delayed initiation of concurrent palliative oncology care: patient outcomes in the ENABLE III randomized controlled trial;Bakitas,2015

5. Carcinoid heart disease;Bernheim,2007

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3